Erythropoietin, an update, and where to in the future?
Recombinant human erythropoietin has been produced by genetic technology since 1985 and since then many clinical trials have repeatedly demonstrated its success in the correction of anaemia associated with renal failure. This paper discusses basic principles for its administration, potential side effects and strategies for non response to erythropoietin (Epo) therapy.
General University Hospital, Department of Medicine, Prague, Czech Republic.
S
S
Sulková
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D016527:Drug Costs; D016903:Drug Monitoring; D004351:Drug Resistance; D004921:Erythropoietin / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D016896:Treatment Outcome
D006397:Hematinics; D004921:Erythropoietin